In PLOS this week: novel RIG-I-like receptor regulators, approach for identifying adaptive genes, and more.
New research suggests Ebola virus may appear in survivor sperm samples some nine months after disease onset, though sexual transmission appears relatively rare.
A majority of respondents said liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, with NGS-based analysis preferred over other testing modalities.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
The kit targets several mRNA biomarkers and is the first in a series of salivary diagnostic kits the firm plans to develop for early-stage disease diagnostics.
An epigenome-wide association study suggests a phenotype called mantling is caused by reduced methylation across a newly detected transposon known as Karma.
Researchers from Stanford University have developed a nine-gene panel and a composite risk model to determine prognosis in non-small cell lung cancer.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.
The latest addition to the firm's qPCR-based Amplidiag line of tests detects H. pylori as well as that pathogen's resistance to clarithromycin.
A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.
Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.
Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.
In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.